Global Viral Hepatitis Market 2025–2029: Competitive Insights and Opportunities

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Viral Hepatitis Industry By The Forecast Year 2029?

The viral hepatitis market size has shown consistent expansion in recent years. It is anticipated to increase from $16.21 billion in 2024 to $16.77 billion in 2025, achieving a compound annual growth rate (CAGR) of 3.4%. Historically, this market’s growth is attributable to advancements such as vaccine development, blood screening programs, the introduction of antiviral drugs, and various global health initiatives.

The viral hepatitis market size is projected to experience consistent expansion over the upcoming years, reaching $19.71 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 4.1%. This anticipated growth during the forecast period is primarily driven by factors such as improved access to treatment, supportive public health legislation, the introduction of combination therapies, and various health equity initiatives. Significant developments expected within this period encompass personalized treatment plans, the adoption of digital health tools, the application of AI in disease monitoring, and efforts towards hepatitis C micro-elimination.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp

Which Factors And Drivers Are Influencing The Viral Hepatitis Market In 2025?

An increasing incidence of hepatitis is projected to fuel the expansion of the viral hepatitis market in the future. This liver infection stems from various infectious viruses and non-infectious agents, leading to multiple health complications. Viral hepatitis, characterized by liver inflammation and damage, can be triggered by viruses such as Hepatitis A, B, C, D and E. As an illustration, the European Centre for Disease Prevention and Control, a government health agency located in Sweden, reported in April 2024 that 28,855 cases of hepatitis B virus (HBV) infection were documented across 30 EU/EEA Member States in 2022, marking a 78% rise from the 16,187 cases recorded in 2021. Furthermore, the overall number of cases in 2022, which totaled 28,420, indicated a crude rate of 8.5 cases per 100,000 people. Consequently, the growing incidence of hepatitis is expected to propel the viral hepatitis market forward.

How Is The Viral Hepatitis Market Segmented?

The viral hepatitismarket covered in this report is segmented –

1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types

2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis

3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments

4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Hepatitis A: Acute Hepatitis A; Chronic Hepatitis A

2) By Hepatitis B: Acute Hepatitis B; Chronic Hepatitis B; Hepatitis B Carrier

3) By Hepatitis C: Acute Hepatitis C; Chronic Hepatitis C

4) By Other Disease Types: Hepatitis D; Hepatitis E

What Are The Major Trends Driving The Growth Of The Viral Hepatitis Market?

Companies operating within the viral hepatitis market are actively working on advancing new drugs and development initiatives to sustain their position. Drug development and innovation enhance scientific understanding by providing insights into disease mechanisms and accelerating the creation of new treatments. For instance, in November 2022, Gilead Sciences Inc., a U.S.-based biopharmaceutical company, announced that the Food and Drug Administration (FDA) had approved the supplemental new medicine application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. This approval designates it as a once-daily medication for treating chronic hepatitis B virus (HBV) infection in children 12 years of age and older who have compensated liver disease. The findings from the 24-week Phase 2 clinical trial supported Vemlidy’s approval for this specific pediatric patient group.

Which Major Firms Are Strengthening Their Position In The Viral Hepatitis Industry?

Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Viral Hepatitis Market?

North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Viral Hepatitis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13028&type=smp

Browse Through More Reports Similar to the Global Viral Hepatitis Market 2025, By The Business Research Company

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Liver Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Human Liver Model Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/human-liver-model-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795